We found a large population of CD8+ T cells in mice treated with Alb-Flt3L plus radiation that were specific for ADPGK (Figure 3, M and N), supporting the idea that Alb-Flt3L potentially serves as an in situ vaccination strategy to uncover antigens and mount tumor-specific cytotoxic T cell immunity regardless of the antigen profile in an individual tumor. This evidence concerns the gene CD8A and neoplasm.